Unknown

Dataset Information

Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials.


ABSTRACT:

Objective

To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients.

Data sources

A systematic review of the MEDLINE and Scopus databases (last search: October 8th, 2021) was performed according to the PRISMA statement.

Study selection

Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible.

Data extraction and synthesis

Individual patient data were extracted from the Kaplan-Meier curves or were obtained from authors of included studies. Additionally, the reviewers independently abstracted data and assessed study quality of each eligible report.

Results

Eleven studies were identified, incorporating 7467 patients (IL-6 inhibitors: 4103, SOC:

SUBMITTER: Tasoudis PT 

PROVIDER: S-EPMC8986475 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature